Ocumension Therapeutics (FRA:5DG) Cash-to-Debt : 7.61 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ocumension Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 7.61.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Ocumension Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Ocumension Therapeutics's Cash-to-Debt or its related term are showing as below:

FRA:5DG' s Cash-to-Debt Range Over the Past 10 Years
Min: 7.61 Med: 157.44 Max: 1772.18
Current: 7.61

During the past 6 years, Ocumension Therapeutics's highest Cash to Debt Ratio was 1772.18. The lowest was 7.61. And the median was 157.44.

FRA:5DG's Cash-to-Debt is ranked better than
52.11% of 1539 companies
in the Biotechnology industry
Industry Median: 6.46 vs FRA:5DG: 7.61

Ocumension Therapeutics Cash-to-Debt Historical Data

The historical data trend for Ocumension Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Ocumension Therapeutics Cash-to-Debt Chart

Ocumension Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

988.66

281.32

157.43

43.57

7.61

Ocumension Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial						157.43	38.81	43.57	41.54	7.61

Competitive Comparison of Ocumension Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Ocumension Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocumension Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Ocumension Therapeutics's Cash-to-Debt falls into.

Ocumension Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Ocumension Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	134.785	/	(16.994	+	0.727)
	=	7.61

Ocumension Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	134.785	/	(16.994	+	0.727)
	=	7.61

Ocumension Therapeutics (FRA:5DG) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Ocumension Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics (FRA:5DG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (FRA:5DG) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

01477:Hong Kong

Address

No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN

Website

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Ocumension Therapeutics (FRA:5DG) Headlines

No Headlines